Business Wire

Chugai's HEMLIBRA® Receives the World's First Regulatory Approval from FDA for Hemophilia A with Inhibitors

Del

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the U.S. Food and Drug Administration (FDA) has approved the bispecific antibody emicizumab (US product name: HEMLIBRA®) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors. This represents the first regulatory approval for HEMLIBRA® around the world. The US Biologics License Application (BLA) was submitted by Genentech, a member of Roche Group.

“We are pleased that HEMLIBRA, a biopharmaceutical created by Chugai scientists based on their exceptional idea, has received its first regulatory approval,” said Chugai’s President & COO, Tatsuro Kosaka. “HEMLIBRA is a first in class biopharmaceutical which is an advancement on the current limited treatment options available for patients with hemophilia A with inhibitors. We anticipate that patients will receive significant potential benefits from HEMLIBRA, which enables once-weekly subcutaneous injection as well as reduction of the bleeding risk.”

This regulatory approval is based on the data from two clinical studies, the results of HAVEN 1 study (NCT02622321) and the interim analysis of HAVEN 2 study (NCT02795767) in patients with hemophilia A with factor VIII inhibitors. HAVEN 1 included adult and adolescent patients and HAVEN 2 included pediatric patients, and were both conducted under a collaboration between Chugai, Roche and Genentech. In the HAVEN 1 study, adults and adolescents with hemophilia A with inhibitors who received HEMLIBRA prophylaxis (n=35) had a statistically significant and clinically meaningful 87% (95% CI: 72.3-94.3, p<0.0001) reduction in treated bleeds compared with those who received no prophylaxis (n=18). Interim results from the HAVEN 2 study, pediatric patients with hemophilia A with inhibitors showed that 87% of patients (95% CI: 66.4-97.2) who received HEMLIBRA prophylaxis (n=23) experienced zero treated bleeds. The most common adverse events (AEs) occurring in 10% or more of people treated with HEMLIBRA in pooled studies were injection site reactions, headache and joint pain (arthralgia).

HEMLIBRA was reviewed by the FDA under Priority Review. It was granted Breakthrough Therapy Designation by the FDA in adults and adolescents with hemophilia A with inhibitors in September 2015. Outside the US, emicizumab has been filed in the EU in June 2017 and data from HAVEN 1 and HAVEN 2 are being reviewed under Accelerated Assessment by the European Medicines Agency. In Japan, the drug received orphan drug designation by the Ministry of Health, Labour and Welfare for the prevention and reduction of bleeding episodes in patients with congenital FVIIl deficiency (hemophilia A) who developed inhibitors to FVIII in August 2016, and a new drug application was filed in July 2017.

About Chugai

Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals, and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.
The consolidated revenue in 2016 of Chugai totaled 491.8 billion yen and the operating income was 80.6 billion yen (IFRS Core basis).
Additional information is available on the internet at https://www.chugai-pharm.co.jp/english.

Contact information

For Media
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
Koki Harada
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp
***
For US media
Chugai Pharma USA Inc.
Paul Mignone
Tel: +1-908-516-1350
E-mail: pr@chugai-pharm.com
***
For European media
Chugai Pharma France SAS
Nathalie Leroy
Tel: +33-1-56-37-05-21
E-mail: pr@chugai.eu
***
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Susan Chou, Osamu Kagawa
Tel: +886-2-2715-2000
E-mail: pr@chugai.com.tw
***
For Investors
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel: +81-3-3273-0554
E-mail: ir@chugai-pharm.co.jp

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Alibaba A.I. Labs Launches Hospitality Robot20.9.2018 04:00Pressemelding

The robotics industry is revolutionizing the world, and Alibaba A.I. Labs is raising the stakes in this cutting-edge industry with the announcement of launching service robots for the hospitality sector starting in October. The news was made at The Computing Conference 2018, which is scheduled for four days till September 22 in Hangzhou, China, the site of Alibaba’s headquarters. Alibaba A.I. Labs is the department leading consumer AI product development at Alibaba. Hotels have until now depended entirely on human labor. But the labs' service robot — from delivering meals to taking laundry to guests — demonstrates what guests can expect at hotels in the future. Guests talk to the robot via voice command, touch and hand gesture, and its responses are driven by AliGenie, the software that powers Alibaba A.I. Labs’ smart speaker, Tmall Genie. “We are excited by this tremendous development that is helping us bridge the gap between guest needs and the response time that they expect. Alibaba

Celltrion Signs 'Incubation' Agreement with Emory University for Development of New Drugs for Atherosclerosis20.9.2018 02:03Pressemelding

Celltrion, Inc. (KRX:068270) signed an ‘Incubation’ agreement with Emory University in Atlanta to support the research and development of new drug candidates for atherosclerosis. ‘Incubation’ agreement is one of the open innovation measures by which a company provides its internal resources and capabilities, such as research space and facility, manpower and business operation consulting, to an external research institute or startup so as to support the research and ensure autonomy of the research aimed at developing new drugs or next-generation technology on the condition that the company can preferentially discuss commercialization of the research output. Under the agreement, Celltrion will share Celltrion’s accumulated biologics development expertise with Emory University School of Medicine and the Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Institute of Technology, and provide research costs and manufacturing materials of new drug candidat

Rimini Street Obtains Australian Single Touch Payroll Certification19.9.2018 23:00Pressemelding

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced it has obtained Single Touch Payroll (STP) certification by the Australian Government’s Australian Taxation Office (ATO) for PeopleSoft Global Payroll and SAP HCM Payroll. The new certification enables Rimini Street’s Australian clients to submit their payroll data via a ‘pay event,’ either on or before pay day, to the ATO. Rimini Street’s tax, legal and regulatory division passed the complex, rigorous qualification process with the first file submission for both PeopleSoft and SAP software products, well ahead of the deadline set by the ATO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180919005857/en/ Rimini Street Obtains Australian Single Touch Payroll Certification (Photo: Business Wire) Premium Service Support for Critica

Litigation Researchers Believe - Dutch Court Ruling - Big Blow to Petrobras’ Arbitration Strategy19.9.2018 22:34Pressemelding

Battea Global Litigation Research, Inc. believes today was a big milestone win for a large group of international investors supporting a coalition of law firms and the Dutch Stichting Petrobras Compensation Foundation (“SPCF” or “Foundation”) in the Netherlands, in their litigation over losses relating to the Petrobras “Lavo Jato” or “Operation Car Wash” scandal. The Rotterdam District Court ruled on whether the Foundation representing investors, who purchased securities outside of the United States, has the right to sue Petrobras in Dutch courts. Petrobras has been fighting investors both in the U.S. and internationally and has sought to drag investors to arbitration in Brazil. However, on January 3, 2018, Petrobras announced that in connection with the losses investors suffered from the “Lavo Jato” bribery scandal, it had agreed to a USD $3 billion settlement with investors who purchased ADRs (American Depository Receipts/American Depository Shares) and USD denominated bonds in the U

BCW Names Jillian Janaczek New York Market Leader19.9.2018 15:50Pressemelding

BCW (Burson Cohn & Wolfe), a leading global communications agency, today announced Jillian Janaczek has been named Executive Vice President, Managing Director, Market Leader for New York, the firm’s largest market globally. In her new role, she will manage talent and operations of the firm’s headquarters office, maintain key client relationships and help drive business growth across all industry sectors. Rachi Govil will assume the role of Executive Vice President, Managing Director, New York Healthcare Practice Leader. “Jillian is a veteran communications professional and leader with deep experience running and growing multimillion dollar clients and large teams,” said Chris Foster, President, North America, BCW, to whom Janaczek will report. “She is also deeply committed to finding and nurturing the best talent in the business. Jillian will be an invaluable partner to me and to our entire organization as she builds the business in our largest market.” Before this role, Janaczek spent

District Court in Rotterdam (Netherlands), Accepts Jurisdiction in Securities Fraud Litigation against Petrobras19.9.2018 15:11Pressemelding

On January 23, 2017, Stichting Petrobras Compensation Foundation (the “Foundation”) initiated an international collective action for Petrobras investors who purchased Petrobras securities outside of the United States and have suffered damages as a consequence of fraud that was uncovered by the “Lavo Jato” or “Operation Car Wash” investigations at the Brazilian petrochemical company that was once the 5th largest company in the world. Petrobras has structured a significant part of its assets through the Netherlands and one of the entities issuing Petrobras securities (Petrobras Global Finance B.V.) is based in Rotterdam, the Netherlands. Moreover Petrobras is benefiting from the Dutch tax environment and Dutch investment protection treaties. Despite its strong nexus with the Dutch jurisdiction, Petrobras strongly contested the jurisdiction of the District Court in Rotterdam. Today the District Court in Rotterdam ruled in favor of the Foundation by accepting jurisdiction. Also the Court r